Evidence map›Paper›PMID 40803659›Full record

ArticleBioorganic & medicinal chemistry letters2025

Development of dihydroquinazoline compounds as novel therapeutics against Naegleria fowleri.

Megan M Voisinet, Caroline M Palmentiero, Jillian E M McKeon, Colm P Roster, Haley M Carlson, Thomas D Brzezinski, Kaylin M Burton, James C Morris, R Adam Mosey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Megan M VoisinetDepartment of Chemistry, Lake Superior State University, Sault Sainte Marie, MI 49783, United States.
Caroline M PalmentieroEukaryotic Pathogens Innovation Center, Department of Genetics and Biochemistry, Clemson University, Clemson, SC 29634, United States.
Jillian E M McKeonEukaryotic Pathogens Innovation Center, Department of Genetics and Biochemistry, Clemson University, Clemson, SC 29634, United States.
Colm P RosterEukaryotic Pathogens Innovation Center, Department of Genetics and Biochemistry, Clemson University, Clemson, SC 29634, United States.
Haley M CarlsonDepartment of Chemistry, Lake Superior State University, Sault Sainte Marie, MI 49783, United States.
Thomas D BrzezinskiDepartment of Chemistry, Lake Superior State University, Sault Sainte Marie, MI 49783, United States.
Kaylin M BurtonDepartment of Chemistry, Lake Superior State University, Sault Sainte Marie, MI 49783, United States.
James C MorrisEukaryotic Pathogens Innovation Center, Department of Genetics and Biochemistry, Clemson University, Clemson, SC 29634, United States.
R Adam MoseyDepartment of Chemistry, Lake Superior State University, Sault Sainte Marie, MI 49783, United States. Electronic address: rmosey@lssu.edu.

Funding

Regulation of Cryptosporidium DevelopmentP20GM146584 · NIGMS · CLEMSON UNIVERSITY · PI KERRY Scot SMITH · 2022 to 2026
$13.5M
Enolase inhibitors as therapeutic leads for Naegleria fowleri infectionsR21AI171217 · NIAID · CLEMSON UNIVERSITY · PI MORRIS, JAMES CULVIN, MOSEMAN, E. ASHLEY · 2023 to 2024
$468k
Approaches for genetic manipulation of Naegleria fowleriR21AI175463 · NIAID · CLEMSON UNIVERSITY · PI MORRIS, JAMES CULVIN · 2023 to 2024
$419k
NIAID NIH HHS R21 AI171217NIAID NIH HHS R21 AI175463NIGMS NIH HHS P20 GM146584
6 · The paper itself

Abstract

Primary amoebic meningoencephalitis (PAM) is a brain infection caused by the free-living amoebae Naegleria fowleri. There are few viable treatment options for the infection, resulting in a >97 % fatality rate. Small molecules are being increasingly investigated as treatment options for this deadly infection. This work details the discovery of a dihydroquinazoline that was toxic to the amoeba and subsequent structure-activity relationship (SAR) development of compounds with increasingly potent activity, yielding several early lead candidates exhibiting submicromolar activity (EC

Indexed as

Antiprotozoal AgentsNaegleria fowleriQuinazolinesDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity RelationshipAntiprotozoal AgentsQuinazolinesBrain-eating amoebaDihydroquinazolinesMulticomponent reactionNaegleria fowleriStructure–activity relationship

Identifiers

PMID40803659
PMCPMC12395418

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.